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Abstract. Although bacteremic pneumococcal pneumonia is the 
most severe form of pneumonia, non-bacteremic forms are much 
more frequent. Laboratory methods for the diagnosis of non-
bacteremic pneumococcal pneumonia have a low sensitivity and 
specificity, and therefore all-cause pneumonia has been proposed 
as a suitable outcome to evaluate vaccination effectiveness.  
      This work reviews the epidemiology  of  community-acquired 
pneumonia (CAP) and evaluates the effectiveness of the 23-valent 
pneumococcal polysaccharide vaccine (PPV-23) in preventing 
CAP requiring hospitalization in people aged ≥65 years.  
      We performed a case-control study in patients aged ≥65 years 
admitted through the emergency department who presented with 
clinical signs and symptoms compatible with pneumonia. We 
included 489 cases and 1,467 controls and it was obtained a 
vaccine efectiveness of 23.6 (0.9-41.0). Our results suggest that 
PPV-23 vaccination is effective and reduces hospital admissions 
due to pneumonia in the elderly, strengthening the rationale for 
vaccination programmes in this age group. 
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Introduction 
 
 Pneumonia is an inflammation of the lung parenchyma located below the 
terminal bronchioles (respiratory bronchioles, alveolar ducts, alveolar sacs 
and alveoli) that leads to impaired gas exchange. The inflammatory reaction 
causes water density in chest X-rays, the hallmark of pulmonary 
consolidation. Pneumonia acquired outside the hospital is known as 
community-acquired pneumonia (CAP), in contrast to nosocomial 
pneumonia, which is acquired after 48 hours of admission to the hospital  or 
the first week after discharge [1].  
 Pneumonia together with influenza is the seventh leading cause of death 
in the United States of America (USA) with a high estimated monthly 
mortality rate of 19.4/100,000 inhabitants [2]. 
 On the basis of a study it was estimated roughly 915,900 cases of CAP 
could occur annually among seniors in the USA and that approximately 1 of 
every 20 persons aged ≥85 years could have a new episode of CAP each year 
[3]. Other studies estimated a number of cases of CAP requiring 
hospitalization in USA of 485,000 patients annually, and 43,000 of these 
persons died [4]. 
 Currently, an etiologic diagnosis is achieved in between 29 and 60% of 
cases of CAP requiring hospital admission, depending on the number of 
samples and techniques used [5-16]. In some studies, the rate exceeds 70%   
[17-19], although the percentage of etiologic diagnoses may be significantly 
lower in hospitals without systematic diagnostic protocols or when patients 
have received prior antibiotic treatment, with some studies finding rates of 
14% [20]  (Tables 1 and  2). 
 CAP is caused by a wide variety of bacterial species, including, in order 
of frequency, Streptococcus pneumoniae, Haemophilus influenzae, 
Chlamydophila pneumoniae, Mycoplasma pneumoniae, Staphylococcus 
aureus, Legionella pneumophila and some enterobacteria [22]. Viral 
infections result in 10-25% of CAP, but the relative frequency of the different 
microorganisms varies according to factors such as age, underlying disease 
and the diagnostic methods used [23].  
 Various studies suggest that between 30 and 50% of cases of CAP 
requiring hospitalization are caused by S. pneumoniae  [6, 8, 24, 25]. 
 Some authors have suggested that the number of cases caused by S. 
pneumoniae is underestimated. A Spanish study found that many patients 
hospitalized with CAP in whom no etiologic diagnosis is obtained using 
routine techniques are diagnosed with pneumococcal pneumonia when more-
sensitive detection techniques are used and samples are obtained by non-
routine procedures such as transthoracic puncture [18, 26].   Ruiz-González et al.  
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Table 1. Percentage of etiologic diagnostic in several studies about CAP in Spain. 
 
 
N=number of CAP studied. 
*Percentage obtained after tests on samples of lung tissue. 
 
found that 33% of cases of pneumonia labelled as of unknown etiology using 
standard methods (blood culture, sputum culture and serology) were finally 
diagnosed as pneumococcal pneumonia after tests on samples of lung tissue 
obtained by transthoracic puncture [18].  
 Studies show that the incidence of CAP varies according to several 
factors: the country where the study is carried out, the age groups included, 
whether the study includes all patients with CAP or only those requiring 
hospitalization, and sex [27, 28].  
 In Spain, the incidence of CAP in adults ranges between 2 and 10 cases 
per 1,000 persons/year, and from 2.3 to 35 per 1,000 persons/year in people 
aged ≥70 years [21, 27, 29, 30]. The incidence of CAP is always greater in 
the elderly and persons with underlying diseases, which, together with the 
ensuing mortality, is a concern for health authorities [25].  Tables 3 and 4 
show figures of incidence in diferents studies in Spain and other countries.  
Conchita Izquierdo et al. 72
Table 2. Percentage of etiologic diagnostic in several studies about CAP in other 
countries. 
 
 
   N=number of CAP studied. 
 
Table 3. Incidence of CAP in Spain. 
 
 
*cases/1000 persons/year. **cases/1000 persons/year in specific groups: age (years) and 
gender. M: men; W: women 
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Table 4. Incidence of CAP in other countries. 
 
 
*cases/1000 persons/year. **cases/1000 persons/year in specific groups: age (years) and 
gender. M: men; W: women 
 
 Although the criteria for hospitalization are not homogeneous, it is 
estimated that between 12 and 50% of patients with pneumonia require 
hospital admission [30-32, 36]. The figures increase with age and can reach 
between 67% and 75% in cases of CAP in people aged ≥65 years [29, 34], 
although some studies have reported figures of 73.2% for all ages [28].  
 The case-fatality rate of CAP is related to the severity of the disease and 
is lower in series that include patients treated as outpatients [27, 28, 31, 33, 
34, 37] in which the rate is ≤5%, with some studies finding no fatalities [21, 
32] (Table 5). 
 The case-fatality rate is higher in patients requiring hospitalization. In 
Spain, several series have reported a rate of around 7% in patients of all ages 
hospitalized for pneumonia [28, 38] with age-related increases being 
observed. 
 The case-fatality rate is much higher in cases of CAP requiring intensive 
care unit admission [37, 39], with a mean of 36.5% [37] and a range of 20-
53% according to the study [40]. 
 Taken together, these data show that the incidence and case-fatality rate of 
CAP are high and, therefore, strategies aimed at their reduction should be sought. 
 The 23-valent pneumococcal polysaccharide vaccine (PPV-23) has been 
available in the USA for 25 years and is currently available in most 
developed countries.  
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Table 5. Hospitalization and case-fatality rate in CAP. 
 
 
N=number of CAP studied. 
 
 The effectiveness of the 13-valent polysaccharide vaccine, the forerunner 
of the current PPV-23 was demonstrated in randomized controlled trials in 
young adults in the 1970s [41-43]. 
 Since 1984, vaccination has been recommended for persons aged ≥65 
years and people aged ≥2 years with risk factors [25, 44, 45]. 
 The current consensus is that observational studies have shown that the 
PPV-23 is effective in preventing invasive pneumococcal disease [42, 46, 
47]. However, vaccination coverages are not high in some countries due to 
doubts about the effectiveness of the PPV-23 in preventing non-bacteremic 
pneumococcal pneumonia [42, 46, 47].  
 Although bacteremic pneumococcal pneumonia is the most severe form, 
non-bacteremic forms are much more frequent [25], with only 10-20% of cases 
of pneumococcal pneumonia in adults being bacteremic. Since laboratory 
Is 23-valent pneumococcal polisaccharide vaccine useful in pneumonia?  75 
methods for the diagnosis of bacteremic pneumococcal pneumonia have a low 
sensitivity and specificity, all-cause pneumonia has been proposed as a suitable 
outcome to evaluate the effectiveness of vaccination [42]. If a significant 
proportion of cases of CAP admitted to hospital are of pneumococcal origin, 
and vaccination is effective against bacteremic and non-bacteremic forms, this 
should result in a reduction in hospitalizations for all-cause CAP. 
 In 1999, various Spanish regions introduced PPV-23 vaccination for 
patients aged ≥65 years into the vaccination schedule [45], in accordance 
with international recommendations [44]. 
 Vaccine coverage in some regions reached 35% in 2001, and 40% 
thereafter [48]. This coverage and the large number of hospitalizations for 
CAP in Spain made it possible to establish the objective of this study: To 
evaluate the effectiveness of PPV-23 in preventing cases of CAP requiring 
hospitalization in people aged ≥65 years. 
 
1. Methods    
 
Study design   
 
 A matched case-control study in patients with CAP admitted to five 
hospitals in three Spanish regions between 1 May 2005 to 31 January 2007 
was carried out [49].  
 A case was defined as a person aged ≥65 years admitted to hospital 
through the emergency department who presented with an infiltrate on chest 
X-ray compatible with pneumonia and one or more of the following 
symptoms or signs of acute lower respiratory tract infection: cough, pleuritic 
chest pain, fever >38ºC, hypothermia <35ºC or dyspnea within the past 24 
hours [25, 50].   Exclusion criteria were institutionalized patients, patients 
with nosocomial pneumonia (onset ≥2 days after hospital admission), patients 
whose initial diagnosis of pneumonia was not confirmed during the hospital 
stay and cases of CAP in whom the pneumococcal and influenza vaccination 
status could not be determined 
 Three hospital controls were selected for each case. Controls were 
admitted through the emergency department with a diagnosis other than 
pneumonia, selected from the admission lists of each participating hospital. 
On selection, the vaccination status of controls was not known and, if the 
status could not be determined later, they were excluded. 
 For each case and control  information on age, sex, dates of 
hospitalization and discharge (alive or dead), history of pneumonia, visit to 
the doctor in the past year, smoking, risk-consumption of alcohol and the 
presence or absence of underlying conditions was obtained. The 
pneumococcal and influenza vaccination status was also collected. 
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 Each case was classified according to the level of risk and the degree of 
immunosuppression associated with the underlying disease: Stratum I (high 
risk) included all patients with conditions associated with 
immunocompromise, stratum II (moderate risk) included immunocompetent 
patients with one or more high-risk medical conditions and stratum III 
included patients not included in strata I or II (Table 6). 
 Each case was matched with three control subjects by sex, age (+/- 5 years), 
date of hospitalization (+/-30 days) and underlying disease and/or stratum. 
 Patient information was obtained through two sources: a) Review of 
written hospital medical records (underlying diseases, alcohol consumption, 
and history of pneumonia and vaccination status) and b) Interview of the 
patient or  close  relatives  (spouse      or     offspring) for visits  to the doctor in the 
past year,  alcohol consumption  and vaccination        status using a  questionnaire 
 
Table 6. Distribution of cases and controls by stratum. 
 
 
*COPD: Chronic obstructive pulmonary disease. 
** AIDS: Acquired immunodeficiency syndrome. 
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completed by qualified staff. Vaccination status was also obtained from the 
vaccination card and health care centre vaccination registers. 
 The vaccination status was ascertained by staff blinded as to whether the 
patient was a case or control. 
 Patients were considered vaccinated when the vaccine had been given ≥15 
days before the onset of pneumonia for cases or ≥15 days before the date of 
hospitalization for controls.  The same criteria were used to determine prior 
influenza vaccination (IV) status. 
 We calculated the minimum required sample size according to 
Schlesselman criteria [51]. 
 We assumed a prevalence of vaccination in the control group of 0.35 [52] 
and vaccine effectiveness (VE) against all-cause pneumonia of 35 %. With an 
alpha error of 0.05 (two-tailed), a beta error of 0.20 and three controls per case, 
we calculated that 269 cases and 807 controls would be needed. Because 
vaccination coverage was estimated to be lower in some of the participating 
regions, we increased the number of cases to 405 and controls to 1,215.  The 
study was approved by the ethic committee of each hospital. 
 
Statistical Analysis 
 
 The differences observed between cases and controls according to the study 
variables were analysed using paired tests. The McNemar chi square test or 
binomial distribution test, when appropriate, was used for categorical variables 
and the paired t-test for continuous variables. A two-tailed distribution for all p 
values and considered p<0.05 to be statistically significant was assumed.  
 Conditional logistic regression (CLR) to account for the effects of 
confounding variables was used. The variables introduced in the CLR 
analysis were influenza vaccine status, variables potentially related to the 
vaccination response and those with a p value <0.1 in the univariate analysis. 
In the final analysis, variables with a significance of p<0.05 were included in 
the model. Adjusted odds ratios (ORs) for immunosuppressed (stratum I) and 
immunocompetent patients (stratum II and III) separately and for all three 
strata combined were calculated. 
 VE was estimated using the formula VE = (1-OR) x 100. 
 The statistical analysis was performed using the SPSS v15.0 statistical 
program.  
 
2. Results  
 
  489 cases and 1,467 controls were included in the analysis; of 489 sets: 
200 (41%) in stratum I, 190 (39%) in stratum II and 99 (20%) in stratum III. 
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 The distribution of study variables was similar in the two groups, 
although more cases than controls had had a previous episode of pneumonia 
[119 (25.3%) vs 192 (13.7); p<0.001]. The only significant differences in the 
distribution of underlying diseases between cases and the three controls were 
in the proportions with solid organ neoplasia [51 (10.4%) in cases vs 304 
(20.7%) in controls; p<0.001], hematologic neoplasia [43 (8.8%) vs 53 
(3.6%); p<0.001],  chronic obstructive pulmonary disease (COPD) [180 
(36.8%) vs 442 (30.1%); p=0.006]; diabetes mellitus [108 (22.1%)  vs 393 
(26.8%); p=0.04] and corticosteroid therapy [24 (4.9%) vs 37 (2.5%); 
p=0.009] showed significant differences between cases and controls.  
 Of 489 sets, 200 were immunosuppressed and 289 immunocompetent.  
 
Vaccination effectiveness  
  
 The unadjusted and adjusted VE according to immune status are shown 
in Table 7. The overall adjusted VE for all three strata combined was 23.6% 
(95% CI: 0.9 to 41.0). For overall VE the significant variables included finally 
in the model were history of pneumonia, solid organ neoplasia, hematologic 
neoplasia, chronic obstructive pulmonary disease and diabetes mellitus.  
  
Table 7. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in 
preventing hospitalization for pneumonia [49]. 
 
 
Data are presented as n, n(%) or % unless otherwise stated.  
OR: Odds ratio. VE: vaccination effectiveness. CI: confidence interval  
*Strata II and III combined. 
#For overall effectiveness, we adjusted for history of pneumonia, solid organ neoplasia, 
hematologic neoplasia, chronic obstructive pulmonary disease and diabetes mellitus.   
For immunosuppressed patients, we adjusted for history of pneumonia, solid organ 
neoplasia, hematologic neoplasia, and chronic obstructive pulmonary disease.  
For immunocompetent patients, we adjusted for history of pneumonia, diabetes mellitus and 
tobacco use. 
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 The adjusted VE for immunosuppressed cases was 21.0% (95% CI: -18.7 
to 47.5). For immunosuppressed patients, the significant variables included in 
the model were history of pneumonia, solid organ neoplasia, hematologic 
neoplasia, and chronic obstructive pulmonary disease. 
 When strata II and III were combined into one group of 
immunocompetent patients, the adjusted VE was 23.6% (95% CI: -7.2 to 
45.6). For immunocompetent patients, the significant variables included in 
the model were a history of pneumonia, diabetes mellitus and smoking. 
 
3. Discussion of results 
 
 We studied the effectiveness of the PPV-23 in preventing CAP requiring 
hospitalization and found an effectiveness of 23.6% (95% CI: 0.9% to 41.0%). 
 Before a vaccine is licensed, its clinical efficacy is evaluated in 
randomized clinical trials [52]. Once licensed for general use, the vaccination 
effectiveness can be assessed in observational studies, which are necessary 
when clinical trials have not provided conclusive results or have not been 
made in the population group for which the vaccine is recommended. 
 The 13-valent pneumococcal polysaccharide vaccine, the forerunner of 
the PPV-23 was evaluated in randomized clinical trials including young adult 
South-African miners [41], and the results encouraged research on its 
effectiveness in the population groups for which it was recommended: people 
aged ≥65 years and those with underlying disease of risk. The results of 
clinical trials in these groups were mostly inconclusive [53-57], suggesting 
that people susceptible to infection may not have an adequate immune 
response to the pneumococcal vaccine evaluated. 
 However, Fedson et al. showed that these studies did not have a sample size 
large enough to obtain conclusive results [42], and pointed out that the outcomes 
assessed in these studies were not always the correct ones. They recommended 
that two outcomes should be assessed in evaluations of the effectiveness of the 
PPV-23: invasive pneumococcal disease (pneumococcal bacteremia) or all-cause 
pneumonia, while other outcomes that have been studied, such as pneumococcal 
pneumonia, lower respiratory tract infections, pneumonia-related deaths and all-
cause mortality not being acceptable [42]. This approach is based on the lack of 
diagnostic methods with sufficient sensitivity and specificity to correctly identify 
non-bacteremic pneumococcal pneumonia. 
 The current consensus is that observational studies have demonstrated 
the effectiveness of the PPV-23 in preventing invasive pneumococcal disease 
[42, 46, 47]. However, vaccination coverages in some countries are not high, 
partly due to doubts about the efficacy of the PPV-23 and its effectiveness in 
preventing non-bacteremic pneumococcal pneumonia [42, 46, 47, 58]. 
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 Our results show that the effectiveness of the PPV-23 in preventing 
hospitalization for pneumonia was 23.6% (95% CI: 0.9% to 41.0%).  
 Although the evidence is limited, some observational studies have shown 
some protective effect of the PPV-23 against hospitalization for CAP (Table 
8). Nichol et al.  [59, 60] and Wagner et al. [61] found that vaccination 
reduced hospital admissions due to all-cause CAP, and reduced the all-cause 
pneumonia case-fatality rate. Nichol et al. carried out a retrospective cohort 
study [59] which included 1,898 patients aged ≥65 years with COPD, and 
found that patients vaccinated with PPV-23 had a lower associated risk of 
hospitalization for CAP [relative risk (RR)= 0.57 (95% CI: 0.38 to 0.84)] and 
a lower risk of death from all causes [RR=0.71 (95% CI: 0.56 to 0.91)]. 
Wagner et al. [61] performed a case-control study of 1,077 residents in a 
geriatric hospital and found a significant reduction in the risk of pneumonia 
in people who received the PPV-23 [OR = 0.28, p <0.001] and a significant 
reduction in the risk of death from all causes [OR = 0.27, p <0.001] and death 
due to pneumonia [OR = 0.33, p <0.001]. Vila-Córcoles et al. [62]  in a 
prospective cohort study of 11,241 subjects, confirmed the protection 
obtained by vaccination with PPV-23 against hospitalization for all-cause 
pneumonia [HR: 0.74 (95% CI: 0.59 to 0.92)] and against death from 
pneumonia [HR: 0.41 (95% CI: 0.23 to 0.72)]. 
 However, Jackson et al. [63] in a retrospective cohort study of 47,365 
people aged ≥65 years between 1998 and 2001, found no reduction in 
hospitalizations due to all-cause CAP [VE= -14% (95% CI:  -28% to -2%)] 
despite finding a significant reduction in pneumococcal bacteremia [VE= 
54% (95% CI: 13% to 76%)] and all-cause mortality [VE= 12% (95% CI: 5% 
to 17%)] in the 38,207 immunocompetent patients. 
 Likewise, neither Ansaldi et al. [64] or Skull et al. [65] found a 
reduction in hospitalizations due to CAP in patients vaccinated with the 
PPV-23. Ansaldi et al. [64] retrospectively studied 9,170 subjects of all 
ages (85.4% aged ≥64 years) for a period of 547,139 person-months, of 
which 71.7% were before and 28.3% after vaccination. They found that, 
in unvaccinated patients, the risk of hospitalization for asthma or otitis 
media was significantly higher, but that although risk of hospitalization 
for pneumonia was somewhat higher in people not vaccinated with PPV-
23 (8.8 % in unvaccinated versus 7.8% in vaccinated subjects), the 
differences were not statistically significant [RR=1.12 (95% CI:0.91       
to 1.38)].  
 Skull et al. [65] evaluated the effectiveness of the PPV-23 in preventing 
hospitalization for CAP in a case-cohort study of patients with a mean age of 
78.4 years, but did not find that vaccination provided any benefits [RR= 0.99 
(95% CI: 0.82 to 1.19]. 
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 In our study, the effectiveness of PPV-23 in preventing hospitalization 
for pneumonia [23.6% (95% CI: 0.9% to 41.0%)] was close to that found by 
Vila-Córcoles et al. [26% (95% CI: 8% to 41%)] [62] and Nichol et al. [27% 
(CI: 95% -13% to 52%)], although in the latter study, the results were not 
statistically significant [60]. The VE in our study was lower than that found 
by Wagner et al. (72.1%) [61]. 
 
Table 8. Observational studies about PPV-23 effectiveness. 
 
 
*Chronic obstructive pulmonary disease. 
 
 A recently published meta-analysis of randomized clinical studies in 
older people failed to demonstrate protection of PPV-23 vaccination against 
all- cause pneumonia [66].  The study evaluated the efficacy of the PPV-23 in 
the prevention of certain clinical outcomes, including all-cause pneumonia. It 
also assessed the methodological quality of the trials analyzed. This meta-
analysis included 22 trials of which the current PPV-23 was only evaluated in 
8. Prevention of all-cause pneumonia was investigated in 19 trials, reducing 
to 11 who were studied in elderly patients or with chronic lung disease. The 
meta-analysis results for these 11 trials showed a  RR = 0.89 (95% CI: 0.69 to 
1.14), but these trials did not specify in which assessed the PPV-23, (and only 
in 8 of the 22 trials analyzed was the PPV-23 used in the study). According to 
information provided, it appears that only 5 of the 11 evaluated the PPV-23. 
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 A 2008 systematic Cochrane review [67] of English-language studies 
evaluating the efficacy and effectiveness of the PPV-23 included 15 
randomized trials and 7 observational studies. The observational studies 
provided evidence of protection against invasive pneumococcal disease in 
populations where the PPV-23 is usually used [OR= 0.48 (95% CI: 0.37 to 
0.61)]. The meta-analysis of the clinical trials also showed the PPV-23 
provided protection against invasive pneumococcal disease [OR= 0.26 (95% 
CI: 0.15 to 0.46)]. The effectiveness of the PPV-23 against all-cause 
pneumonia was not proven because, although the OR was significant [OR = 
0.71 (95% CI: 0.52 to 0.97)] with a VE of 29% [95% CI: 3% to 48%], the 
meta-analysis had substantial statistical heterogeneity. The PPV-23 was 
associated with a not significant reduction in all-cause mortality [OR = 0.87 
(95% CI: 0.69 to 1.10)]. 
 Our study found an effectiveness of the PPV-23 in preventing 
hospitalization for all-cause CAP of 23.6%. It is estimated that only 30-50% 
of cases of CAP are due to S. pneumoniae [25] and therefore the 
effectiveness of the PPV-23 against pneumococcal pneumonia (bacteremic 
and non-bacteremic) would be expected to be higher. In the study by Austrian 
et al. [41] carried out in South African miners with the 13-valent 
pneumococcal polysaccharide vaccine, the VE was 82% against bacteremic 
pneumococcal pneumonia and 78.5% against pneumococcal pneumonia 
(diagnosed by sputum and blood cultures). Observational studies have shown 
that the PPV-23 prevents 50-70% of cases of invasive pneumococcal disease 
(due to all serotypes)  [25, 42]. If 30-50% of all cases of CAP in our 
population are caused by S. pneumoniae, our findings suggest that if the level 
of protection against all-cause CAP was 23.6%, the level of protection 
against pneumococcal pneumonia would be near the level of protection (50-
70%) found in observational studies of invasive pneumococcal disease [46]. 
 Our study, like other observational studies, has strengths and limitations. 
One strength was the size of the sample (489 cases and 1,467 controls), 
which yielded statistically significant results for the overall study population. 
The adjusted overall VE was 23.6% (95% CI: 0.9% to 41.0%). The lack of 
statistical significance in immunocompetent patients may be due to a sample 
size that was not sufficient to study the effectiveness of groups according to 
the immune status. 
 In case-control studies of vaccination there is always a possibility of bias 
that distorts the results and reduces the validity of the findings [68]. One 
source of bias is the assessment of vaccination status in patients. However, in 
our study, information on the vaccination status was obtained retrospectively 
by investigators who were unaware of whether the patient was a case or a 
control, using the records of the same primary care centres for cases and 
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controls, and therefore this point is moot. Moreover, the vaccination status 
was investigated in all primary care centres to which the patient was assigned 
since the PPV-23 was introduced in the vaccination programme (2000). 
 To control for confounding variables, controls were matched with cases 
by date of hospitalization, age, sex and underlying diseases that could 
influence the disease incidence. Even so, statistically significant differences 
between cases and controls were observed for some variables: history of 
pneumonia, solid organ malignancy, hematologic malignancy, corticosteroid 
treatment, diabetes mellitus and COPD. The explanation is that pairing was 
carried out taking into account the disease with greater immunosuppression 
or the longest evolution, but many patients had more than one disease. To 
avoid the possible confounding effect of these variables, we adjusted the 
results using conditional logistic regression. Influenza vaccination could have 
a confounding effect when assessing the protective effect of the vaccine. 
However, we believe that this possibility was minimized as the variable was 
always introduced into the conditional logistic regression analysis.  
 
4. Conclusion 
 
 The incidence of CAP is always greater in the elderly and persons with 
underlying diseases, and between 30 and 50% of cases of CAP requiring 
hospitalization are caused by S. pneumoniae. Therefore the reduction of 
pneumonia-related morbidity partially will depend on the improved use of 
preventive strategies such as immunization against S. pneumoniae.  
 In our study, the overall effectiveness of the PPV-23 in preventing 
hospitalization for pneumonia is estimated at 23.6% (95% CI: 0.9% to 
41.0%). Current recommendations on PPV-23 vaccination are based on 
studies of vaccine effectiveness against invasive pneumococcal disease. Our 
results suggest that the PPV-23 is effective and reduces hospital admissions 
due to pneumonia in the elderly, thereby reinforcing the application of 
vaccination programmes in this age group. 
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